FDA approves first RSV vaccine for at-risk adults in their 50s CBS NewsFDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach CNBC3 Reasons to Buy Moderna Stock Yahoo FinanceGSK exec lauds ‘great start’ to RSV vaccine uptake as Arexvy nabs label expansion in adults 50-59 FiercePharmaGSK’s RSV vaccine receives expanded FDA approval STAT